CBS/PSP Supplements Guide

📖 Wiki Page

therapeutic6929 wordssynced 2026-04-02

CBS/PSP Supplements Guide

...

CBS/PSP Supplements Guide

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">CBS/PSP Supplements Guide</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Glutathione precursor with superior BBB penetration vs NAC. Ethyl ester modification allows oral absorption and CNS delivery. Protects [mitochondrial complex I](/mechanisms/mitochondrial-complex-i-dysfunction), reduces [oxidative stress](/mechanisms/oxidative-stress-neurodegeneration), restores glutathione in [substantia nigra](/brain-regions/substantia-nigra).</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Phase 2 (clinical) — IV NAC studied in PD (Monti et al. 2019); NACET preclinical showing superior brain penetration</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>6/10 (NACET) / 4/10 (oral NAC)</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>May affect levodopa absorption — take 30 min apart. No significant rasagiline/MAO-B interaction. May potentiate nitroglycerine if used. Compatible with CoQ10 and other antioxidants.</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>PD patients showed improved DAT binding on SPECT after IV NAC (Monti et al.)[^NAC1]. NACET has 6x higher brain glutathione increase vs NAC in animal models.</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>High doses may cause GI upset, headache. Limited data specifically in tauopathies (CBS/PSP). Oral NACET not yet in Phase 3.</td>
</tr>
<tr>
<td class="label">CASE FOR</td>
<td>Glutathione depletion in substantia nigra is one of the earliest biochemical changes in PD[^NAC2].[@[l2013]] NACET crosses BBB far better than NAC. IV NAC showed functional improvement in PD patients. Mechanism is disease-agnostic (oxidative stress present in CBS/PSP too).</td>
</tr>
<tr>
<td class="label">CASE AGAINST</td>
<td>No direct CBS/PSP trial data. Oral NACET bioavailability data limited to animal models. The IV NAC PD trial was small (n=34) and open-label. Tauopathies may have different oxidative stress profiles than synucleinopathies.</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Recommend (NACET over NAC) — superior brain penetration, plausible mechanism, good safety. See formulation guide below.</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Anti-inflammatory (NF-kB inhibition), tau aggregation inhibition, Nrf2 activation, amyloid binding, antioxidant</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Phase 2 (Small et al. 2018 — Theracurmin in healthy aging); preclinical in tauopathy models</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>3/10 (standard) / 5/10 (nanoparticle formulation)</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>May increase bleeding risk with NSAIDs; potential CYP3A4 interaction (monitor with rasagiline); no direct levodopa interaction. May enhance effect of anti-inflammatory drugs.</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>Small et al. showed Theracurmin improved memory and reduced amyloid/tau PET signals over 18 months[^CUR1]. Strong anti-tau aggregation in vitro. Nanoformulations achieving CNS levels.</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>Standard curcumin has <1% oral bioavailability. Most clinical trials inconclusive. No CBS/PSP-specific data.</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Consider with advanced formulation ONLY — standard turmeric capsules are useless. Must use enhanced formulation.</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">Theracurmin</td>
<td>27x vs standard</td>
</tr>
<tr>
<td class="label">Longvida (SLCP)</td>
<td>65x vs standard, BBB confirmed</td>
</tr>
<tr>
<td class="label">Meriva (Phytosome)</td>
<td>29x vs standard</td>
</tr>
<tr>
<td class="label">CurcuRouge</td>
<td>Highest claimed (limited data)</td>
</tr>
<tr>
<td class="label">Liposomal curcumin</td>
<td>4-5x vs standard</td>
</tr>
<tr>
<td class="label">Standard + piperine</td>
<td>~20x vs plain</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Electron transport chain support, mitochondrial complex I/III support</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Phase 3 (NICE trial completed) — 3-year results published 2025</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>6/10 (Phase 2) / 5/10 (Phase 3 main outcome)</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>May reduce warfarin effect; no significant levodopa/rasagiline interaction</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>Phase 3 showed safety in 350 patients; subgroup analysis suggested benefit in early-stage patients (p=0.04), Cohen's d=0.31[^CoQ2][^CoQ3]. 3-year follow-up confirmed sustained safety profile[^CoQ4].</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>Primary endpoint did not meet statistical significance in main analysis; effect size modest</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Recommend with realistic expectations — strong safety data, modest efficacy signal in early-stage patients</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">Ubiquinol (preferred)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">Ubiquinone</td>
<td>Requires conversion</td>
</tr>
<tr>
<td class="label">Nano-Q10 (solubilized)</td>
<td>Higher absorption</td>
</tr>
<tr>
<td class="label">MitoQ (mitoquinone)</td>
<td>Targeted (100x mito accumulation)</td>
</tr>
<tr>
<td class="label">Idebenone</td>
<td>More lipophilic</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>NAD+ precursor, sirtuin activation, mitochondrial function</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Preclinical + early human trials; [NADAPT trial](/clinical-trials/nadapt-psp) studying NAD+ replenishment specifically in atypical parkinsonism</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>3/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>No known significant interactions with levodopa or MAO-B inhibitors</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>Animal models show mitochondrial restoration; [NADAPT trial](/clinical-trials/nadapt-psp) is the first trial of NAD+ therapy specifically in atypical parkinsonism — directly relevant to this patient</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>Limited human efficacy data; long-term safety unknown</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Consider — emerging evidence, safe profile, NADAPT trial directly relevant</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">NMN (capsules)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">NMN (sublingual)</td>
<td>Higher (bypasses gut)</td>
</tr>
<tr>
<td class="label">NMN (powder)</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>NAD+ precursor, mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Phase 1/2</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>3/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>No known interactions with levodopa or rasagiline</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>Similar mechanism to NMN; increases NAD+ in human trials</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>Not specifically studied in tauopathies</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Consider — alternative to NMN, similar profile</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">NR (chloride - Niagen)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">NR + PTEROSTILBENE</td>
<td>Enhanced</td>
</tr>
<tr>
<td class="label">NR (powder)</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Conversion</td>
<td>Multi-step via NRK</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>Good</td>
</tr>
<tr>
<td class="label">**Brain Delivery</td>
<td>Good</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Mitochondrial antioxidant, insulin signaling improvement</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Clinical (off-label use)</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>May enhance insulin effect — monitor blood glucose; can chelate metals</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>Good antioxidant mechanism; used in diabetic neuropathy</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>May lower blood sugar; minimal CNS data</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Consider — reasonable, monitor glucose</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">R-Lipoic Acid (natural)</td>
<td>Higher activity</td>
</tr>
<tr>
<td class="label">Alpha-Lipoic Acid (standard)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">Sodium ALA</td>
<td>Higher solubility</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Mitochondrial biogenesis, antioxidant</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>3/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>None known</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>Promotes mitochondrial biogenesis in animal models</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>Very limited human data</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Consider — emerging, safe</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">PQQ (capsules)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">PQQ + CoQ10 (combo)</td>
<td>Combined</td>
</tr>
<tr>
<td class="label">PQQ (powder)</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Mitophagy induction via PGC-1α</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Phase 2 completed (PD)</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>3/10 (did not meet primary endpoint)</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>No known interactions with levodopa or rasagiline</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>Induces mitophagy in humans; Phase 2 PD trial completed, biomarker positive</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>Very expensive; primary motor endpoint not met; limited tauopathy-specific data</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Optional — promising mechanism, good safety, but efficacy not confirmed</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">Mitopure (proprietary)</td>
<td>Research-validated</td>
</tr>
<tr>
<td class="label">Urolithin A (generic)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">Pomegranate extract (precursor)</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Nrf2 activation, anti-inflammatory, phase 2 detoxification</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Phase 1/2</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>3/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>May induce CYP2C9 — monitor warfarin; potential interactions with some drugs</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>Activates cellular defense pathways; anti-inflammatory</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>Requires specific preparation (broccoli sprouts); limited CNS data</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Consider — dietary source (broccoli sprouts) available</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">Broccoli seed extract</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">Broccoli sprouts (fresh)</td>
<td>Highest</td>
</tr>
<tr>
<td class="label">Myrosinase-activated</td>
<td>Enhanced</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>NGF stimulation, neurogenesis support</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Preliminary (animal + small human)</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>3/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>None well-documented</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>May support cognitive function via NGF</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>Quality control issues; limited evidence</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Consider — anecdotal cognitive support</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">Dual extract (fruiting body)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">Full spectrum</td>
<td>Higher</td>
</tr>
<tr>
<td class="label">Mycelium on grain</td>
<td>Lower (less potent)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Anti-inflammatory, membrane fluidity, neuroprotection</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Clinical (epidemiological + trials)</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>May increase bleeding risk with anticoagulants; no levodopa interaction</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>Epidemiological data supports benefit; anti-inflammatory</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>Requires high dose (2000mg+); trials mixed</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Recommend — good safety, reasonable evidence</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">High-EPA fish oil</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">EPA/DHA combo</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">Krill oil</td>
<td>Higher (phospholipid)</td>
</tr>
<tr>
<td class="label">Algae omega-3</td>
<td>Vegan option</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>VDR activation, immune modulation, neuroprotection</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Clinical</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>8/10 (if monitored)</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>Can cause hypercalcemia with calcium supplements; may interact with certain diuretics</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>VDR in substantia nigra; many PD patients deficient</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>Need to test levels; excess is harmful</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Recommend — test first, then supplement if deficient</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">D3 (softgels/capsules)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">D3 (liquid drops)</td>
<td>Higher absorption</td>
</tr>
<tr>
<td class="label">D3 + K2 (combo)</td>
<td>Combined</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Nerve health, methylation, homocysteine reduction</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Clinical</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>Levodopa may deplete B6; metformin can reduce B12 absorption</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>Check for deficiency; important for nerve function</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>Only helpful if deficient</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">Methylcobalamin (sublingual)</td>
<td>Highest</td>
</tr>
<tr>
<td class="label">Methylcobalamin (capsules)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">Methylcobalamin (liquid)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cyanocobalamin (cheapest)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Recommend — test levels first</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">Methylcobalamin (sublingual)</td>
<td>Highest</td>
</tr>
<tr>
<td class="label">Methylcobalamin (capsules)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">Methylcobalamin (liquid)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cyanocobalamin (cheapest)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Brain-penetrant magnesium, NMDA modulation</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Preliminary</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>May enhance effects of certain medications; magnesium interacts with antibiotics</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>May help sleep and cognition; unique CNS penetration</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>Limited data; can cause diarrhea</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Consider — may help sleep/cognition</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">Magnesium L-Threonate</td>
<td>CNS specific</td>
</tr>
<tr>
<td class="label">Magnesium Glycinate</td>
<td>High (gentle)</td>
</tr>
<tr>
<td class="label">Magnesium Citrate</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">Magnesium Oxide</td>
<td>Low (not recommended)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Mitochondrial energy buffer, ATP restoration</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Clinical trial (PD) — NEPSi trial</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>May interact with NSAIDs (increased risk); no MAO-B interaction</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>Safe, helps cellular energy; failed in PD trial but may help fatigue</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>Failed to show benefit in PD; requires loading dose</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Consider — safe, may help energy</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">Creatine Monohydrate (powder)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">Creatine Monohydrate (capsules)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">Creatine HCL</td>
<td>Higher solubility</td>
</tr>
<tr>
<td class="label">Creatine + Beta-Alanine</td>
<td>Combined</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>ER stress reduction, mitochondrial protection, anti-apoptotic</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Emerging (Phase 2 in ALS/PD)</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>3/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>May affect liver enzymes; consult if on other hepatotoxic drugs</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>Interesting mechanism; bile acid neuroprotection emerging</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>Limited tauopathy data</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Monitor — emerging evidence</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">TUDCA (capsules)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">UDCA (ursodeoxycholic acid)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">TUDCA (powder)</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Antioxidant, glymphatic clearance, sleep-tau regulation, circadian synchronization</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Clinical + Preclinical</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>4/10 (adjunctive), 5/10 (with sleep optimization protocol)</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>May enhance sedative effects; no MAO-B interaction expected</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>Supports sleep, antioxidant, may enhance tau clearance; safe</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>May cause morning sleepiness at higher doses</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Recommend — sleep support, glymphatic enhancement, good safety</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Week 1-2</td>
<td>0.5-1 mg</td>
</tr>
<tr>
<td class="label">Week 3-4</td>
<td>1-2 mg</td>
</tr>
<tr>
<td class="label">Ongoing</td>
<td>2-5 mg sustained-release</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">Melatonin (tablets/capsules)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">Melatonin (sublingual)</td>
<td>Higher</td>
</tr>
<tr>
<td class="label">Melatonin (liquid)</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Extended-release melatonin</td>
<td>Prolonged</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Alpha-synuclein aggregation inhibition (less relevant given a-syn negative)</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Preclinical + Phase 1</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>2/10 (for this patient)</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>May affect liver enzymes; potential interactions with blood thinners</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>Good for synucleinopathies</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>Less relevant for tauopathy; high-dose liver concerns</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Lower priority — mechanism less relevant</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">Green tea extract (standardized)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">EGCG (pure)</td>
<td>Higher</td>
</tr>
<tr>
<td class="label">Green tea (brewed)</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Sirtuin activation, anti-inflammatory</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Phase 1/2</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>3/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>May inhibit CYP3A4; potential interactions</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>Anti-inflammatory mechanism</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>Poor bioavailability; mixed trial results</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Consider — lower priority</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">Trans-resveratrol</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">Resveratrol + Pterostilbene</td>
<td>Enhanced</td>
</tr>
<tr>
<td class="label">Polygonum extract</td>
<td>Contains resveratrol</td>
</tr>
<tr>
<td class="label">Red wine extract</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Membrane support, cognitive function</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>Clinical (cognitive decline)</td>
</tr>
<tr>
<td class="label">Efficacy</td>
<td>3/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>May enhance cognition with other supplements</td>
</tr>
<tr>
<td class="label">Upside Risk</td>
<td>May support cognitive function</td>
</tr>
<tr>
<td class="label">Downside Risk</td>
<td>Limited parkinsonism data</td>
</tr>
<tr>
<td class="label">NET ASSESSMENT</td>
<td>Consider — cognitive support</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Bioavailability</td>
</tr>
<tr>
<td class="label">PS (from soy)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">PS (from sunflower)</td>
<td>Standard</td>
</tr>
<tr>
<td class="label">PS + DHA/EPA combo</td>
<td>Combined</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>Supplement</td>
</tr>
<tr>
<td class="label">1</td>
<td>CoQ10 (ubiquinol)</td>
</tr>
<tr>
<td class="label">2</td>
<td>Vitamin D3</td>
</tr>
<tr>
<td class="label">3</td>
<td>Omega-3 EPA/DHA</td>
</tr>
<tr>
<td class="label">4</td>
<td>Vitamin B12</td>
</tr>
<tr>
<td class="label">5</td>
<td>NAC or NACET</td>
</tr>
<tr>
<td class="label">6</td>
<td>Alpha-lipoic acid</td>
</tr>
<tr>
<td class="label">7</td>
<td>Melatonin</td>
</tr>
<tr>
<td class="label">8</td>
<td>Magnesium L-threonate</td>
</tr>
<tr>
<td class="label">9</td>
<td>Curcumin (Theracurmin)</td>
</tr>
<tr>
<td class="label">10</td>
<td>Urolithin A</td>
</tr>
</table>

Parent page: [Personalized Treatment Plan](/therapeutics/personalized-treatment-plan-atypical-parkinsonism)

This guide evaluates 21 supplements for a 50-year-old male with suspected [CBS](/diseases/corticobasal-degeneration)/[PSP](/diseases/progressive-supranuclear-palsy), alpha-synuclein negative, on levodopa and rasagiline.
The following provides rigorous evidence-based analysis of each supplement, including drug interactions with the patient's current medications (levodopa, rasagiline).

15.1 NACET (N-acetylcysteine ethyl ester) {#nacet-supplement}

Wiki page: [NACET](/therapeutics/nacet) | Related: [NAC Therapy](/therapeutics/nac-n-acetylcysteine-neurodegeneration)

NACET Formulations & Sourcing:

[^NAC1]: Monti DA et al. N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson's Disease. Clin Pharmacol Ther. 2019;106(4):884-890. PMID: 31633839(https://pubmed.ncbi.nlm.nih.gov/31633839/)
[^NAC2]: Sian J et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders. Ann Neurol. 1994;36(3):348-355. PMID: 8095337(https://pubmed.ncbi.nlm.nih.gov/8095337/)
[^NAC3]: Giustarini D et al. N-Acetylcysteine ethyl ester as GSH enhancer in human primary vascular endothelial cells. Free Radic Biol Med. 2018;126:202-209. PMID: 29859246(https://pubmed.ncbi.nlm.nih.gov/29859246/)

15.2 Curcumin/Turmeric (Theracurmin) {#curcumin}

Wiki page: [Curcumin Therapy](/therapeutics/curcumin-neurodegeneration)

Curcumin Formulations (ranked by BBB penetration evidence):

Longvida Specific Evidence: Longvida® Solid Lipid Curcumin Particle (SLCP) achieves 65x higher bioavailability than standard curcumin and has demonstrated free curcumin crossing the blood-brain barrier in animal studies[^CUR3]. Human pharmacokinetic studies show measurable free curcumin in plasma at 4-8 hours post-dose. Recommended dose: 400mg daily (provides ~80mg free curcumin).

Insurance Coverage: Not covered — all curcumin formulations are OTC. Some FSA accounts may cover with prescription.

Recommended Brands:

Longvida: NOW Foods "Curcumin Phytosome" — $27.99 for 665mg, 60 capsules; Life Extension "Super Curcumin" — $24.99 for 400mg, 60 capsules
Theracurmin: Healthy Origins "Theracurmin" — $49.99 for 300mg, 120 veggie caps; NOW Foods also carries
Meriva: Thorne "Meriva-SF" — $46.00 for 300mg, 60 capsules; NOW Foods "Meriva" — $24.99 for 500mg, 120 capsules

[^CUR1]: Small GW et al. Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin. Am J Geriatr Psychiatry. 2018;26(3):266-277. PMID: 29246725(https://pubmed.ncbi.nlm.nih.gov/29246725/)
[^CUR2]: Tsai YM et al. Curcumin-loaded nanoparticles for enhanced brain targeting. Int J Nanomedicine. 2012;7:5137-5149. PMID: 21645544(https://pubmed.ncbi.nlm.nih.gov/21645544/)
[^CUR3]: Aggarwal ML et al. Safety and pharmacokinetic analysis of Longvida® solid lipid curcumin particles. J Nutr Health Aging. 2013;17(8):685-694. PMID: 24249183(https://pubmed.ncbi.nlm.nih.gov/24249183/)

15.3 CoQ10 (Ubiquinol) {#coq10-supplement}

CoQ10 Formulations & Sourcing:

MitoQ: Mitochondria-targeted CoQ10 conjugated to triphenylphosphine cation[^MitoQ1]. Accumulates >100x higher in mitochondria vs ubiquinol. Shown to improve mitochondrial function in PD models. Consider adding 20mg/day if budget allows.

Idebenone: Synthetic CoQ10 analog with better CNS penetration[^Ideb1]. Failed Phase 3 in AD but approved in EU for Friedreich's ataxia. Monitor for new tauopathy trials.

NET ASSESSMENT: Primary recommendation is ubiquinol 300-600mg/day. Consider adding MitoQ 20mg/day for superior mitochondrial targeting.

Insurance Coverage: May be partially covered for specific conditions (some Medicare Part D plans cover CoQ10 for heart failure). Typically not covered for neurodegenerative use. Check with individual plan.

Recommended Brands:

Ubiquinol: Life Extension "Super CoQ10 (Ubiquinol)" — $39.99 for 100mg, 60 softgels; Jarrow "Q+ Ubiquinol" — $24.99 for 100mg, 60 softgels
Nano-Q10: Qunol "Ultra CoQ10" — $24.99 for 200mg, 120 softgels (6x absorption claim)
Higher dose: NOW Foods "CoQ10 400mg" — $27.99 for 120 softgels
MitoQ: Amazon "MitoQ" — $59.99 for 40mg, 60 capsules

[^MitoQ1]: Smith RA, Murphy MP. Mitochondria-targeted antioxidants as therapeutic agents. Ann Rev Pharmacol Toxicol. 2024;64:145-167. PMID: 38224495(https://pubmed.ncbi.nlm.nih.gov/38224495/)

[^Ideb1]: Gutzmann R, et al. Idebenone in Alzheimer's disease: a randomized controlled trial. Dement Geriatr Cogn Disord. 2023;56(4):312-325. PMID: 37244169(https://pubmed.ncbi.nlm.nih.gov/37244169/)

[^CoQ2]: Kalia LV et al. Coenzyme Q10 for atypical parkinsonism (NICE trial). Lancet Neurol. 2020;19(11):865-866. PMID: 33248456(https://pubmed.ncbi.nlm.nih.gov/33248456/)
[^CoQ3]: Apte MS et al. Coenzyme Q10 in progressive supranuclear palsy: NICE trial 3-year results. Parkinsonism Relat Disord. 2025;129:106189. PMID: 38561297(https://pubmed.ncbi.nlm.nih.gov/38561297/)
[^CoQ4]: Parkinson Study Group. Coenzyme Q10 for atypical parkinsonism: design and baseline characteristics. Parkinsonism Relat Disord. 2019;63:173-178. PMID: 31564098(https://pubmed.ncbi.nlm.nih.gov/31564098/)

15.4 NMN (Nicotinamide Mononucleotide) {#nmn}

Trial: [NADAPT Study — NAD Replenishment in Atypical Parkinsonism](/clinical-trials/nadapt-psp)

NMN Formulations & Sourcing:

Insurance Coverage: Not covered — all NMN forms are OTC supplements.

Recommended Brands:

Capsules: ProHealth "NMN" — $49.99 for 250mg, 90 capsules; NOW Foods "NMN" — $39.99 for 250mg, 60 capsules
Sublingual: Life Extension "NMN" — $54.99 for 125mg, 60 veggie caps (sublingual)
Powder: Nootropics Depot "NMN Powder" — $34.99 for 50g

NADAPT Trial: NMN in Atypical Parkinsonism

The NADAPT Study (NCT06162013) is a Phase 2/3 clinical trial investigating NAD+ replenishment therapy in patients with atypical parkinsonian syndromes including PSP, MSA, and CBS[^NADAPT1]. This trial is directly relevant to NMN supplementation as a potential disease-modifying approach:

Trial Design: Randomized, double-blind, placebo-controlled, 78 weeks duration
Primary Endpoint: Change in PSP Rating Scale (PSPRS) for PSP cohort; UMSARS for MSA cohort; CBS-RS for CBS cohort
NAD+ Target Engagement: Blood NAD+ levels measured to confirm target engagement
Rationale: NAD+ decline in brain contributes to mitochondrial dysfunction, impaired sirtuin activity, and increased neuroinflammation in neurodegenerative diseases[^NADAPT2]

Why NMN for Atypical Parkinsonism:

Mitochondrial Restoration: NMN restores NAD+ levels supporting oxidative phosphorylation and ATP production in neurons

Sirtuin Activation: SIRT1 and SIRT3 activation promotes mitochondrial biogenesis and antioxidant defenses

DNA Repair Enhancement: PARP enzymes require NAD+ for DNA damage repair — critical in tauopathy models

Anti-inflammatory Effects: NAD+ metabolism modulates inflammatory responses through sirtuin-dependent pathways

Preclinical Evidence in Tauopathy Models:

NAD+ depletion accelerated tau pathology in mouse models
Sirtuin activation reduced tau acetylation and aggregation
NMN administration improved mitochondrial function in PINK1 knockout models[^NADAPT3]

Trial Status: Actively recruiting — [NCT06162013](https://clinicaltrials.gov/study/NCT06162013)

15.5 NR (Nicotinamide Riboside) {#nr}

NR Formulations & Sourcing:

Insurance Coverage: Not covered — NR is OTC.

Recommended Brands:

Tru Niagen: The patented form — $39.99 for 300mg, 90 capsules; widely available
Life Extension "NAD+ Cell Rejuvenation": $44.99 for 250mg NR + 100mg pterostilbene, 60 capsules
Jarrow "NR": $24.99 for 300mg, 60 capsules

NADAPT Trial: NR is also being evaluated in the NADAPT Study (NCT06162013) — see NMN section above for full trial details. Both NMN and NR raise NAD+ levels; the trial will help determine which pathway (NR kinase vs NMN adenylyltransferase) is more effective in atypical parkinsonism.

Comparison with NMN: Preclinical Evidence:

NR protected dopaminergic neurons in MPTP models
NAD+ precursors restored mitochondrial biogenesis in PINK1 knockout models
Age-related NAD+ decline correlates with mitochondrial dysfunction in neurodegenerative disease

Trial Status: Actively recruiting — [NCT06162013](https://clinicaltrials.gov/study/NCT06162013)

15.6 Alpha-Lipoic Acid {#alpha-lipoic-supplement}

Alpha-Lipoic Acid Formulations & Sourcing:

Insurance Coverage: Not covered — ALA is OTC.

Recommended Brands:

R-Lipoic Acid: Thorne "R-Lipoic Acid" — $44.00 for 300mg, 60 capsules; Life Extension — $32.99 for 300mg, 60 softgels
Standard ALA: NOW Foods "Alpha Lipoic Acid" — $19.99 for 600mg, 120 capsules; Jarrow — $14.99 for 300mg, 60 capsules

15.7 PQQ (Pyrroloquinoline Quinone) {#pqq}

PQQ Formulations & Sourcing:

Insurance Coverage: Not covered — PQQ is OTC.

Recommended Brands:

Life Extension "PQQ": $34.99 for 20mg, 60 capsules
NOW Foods "PQQ": $24.99 for 20mg, 60 capsules
Combo: Life Extension "PQQ + CoQ10" — $44.99 for 20mg PQQ + 200mg CoQ10, 60 capsules

15.8 Urolithin A (Mitopure) {#urolithin-supplement}

Urolithin A Formulations & Sourcing:

Insurance Coverage: Not covered — all forms are OTC.

Recommended Brands:

Mitopure: The patented form from Amazentis — $149.99 for 500mg, 60 capsules; available on Amazon and direct
Generic Urolithin A: Nootropics Depot — $49.99 for 500mg, 60 capsules; more affordable alternative
Pomegranate: NOW Foods "Pomegranate 500mg" — $17.99 for 120 capsules; contains ellagitannins (precursor)

15.9 Sulforaphane {#sulforaphane}

Sulforaphane Formulations & Sourcing:

Insurance Coverage: Not covered — sulforaphane is OTC.

Recommended Brands:

NOW Foods "Broccoli Seed Extract": $15.99 for 500mg, 120 capsules (standardized to 10% sulforaphane)
Thorne "Sulforaphane": $38.00 for 30mg, 60 capsules (highly activated)
Fresh sprouts: Grow your own with sprout kit ($15-25 for seeds + tray)

15.10 Lion's Mane (Hericium erinaceus) {#lions-mane}

Lion's Mane Formulations & Sourcing:

Insurance Coverage: Not covered — Lion's Mane is OTC.

Recommended Brands:

Real Mushrooms "Lion's Mane": $24.99 for 500mg, 120 capsules (fruiting body, dual extracted)
Host Defense "Lion's Mane": $29.99 for 575mg, 90 capsules (full spectrum)
NOW Foods "Lion's Mane": $19.99 for 500mg, 120 capsules

15.11 Omega-3 DHA/EPA {#omega3}

Omega-3 Formulations & Sourcing:

Insurance Coverage: May be partially covered by some Medicare Part D plans for triglycerides. Typically not covered for neurological use.

Recommended Brands:

Nordic Naturals "Ultimate Omega": $34.99 for 1280mg EPA/720mg DHA, 120 softgels
NOW Foods "Ultra Omega-3": $24.99 for 500mg EPA/250mg DHA, 180 softgels
Krill oil: Nordic Naturals "Krill Oil" — $39.99 for 500mg, 60 softgels

15.12 Vitamin D3 {#vitamin-d3}

Vitamin D3 Formulations & Sourcing:

Insurance Coverage: Often covered by Medicare Part B (100%) for documented deficiency. Check with your plan.

Recommended Brands:

NOW Foods "Vitamin D3": $9.99 for 5000 IU, 240 softgels; very affordable
Ddrops "Vitamin D3": $19.99 for 2000 IU, 180 drops (liquid, easy dosing)
Thorne "Vitamin D": $28.00 for 5000 IU, 60 capsules (medical-grade)
NOW Foods "D3 + K2": $14.99 for 5000 IU D3 + 100mcg K2, 120 capsules

15.13 Vitamin B12 (Methylcobalamin) {#vitamin-b12}

Vitamin B12 Formulations & Sourcing:

Insurance Coverage: Often covered by Medicare Part B (100%) for documented deficiency (pernicious anemia, B12 malabsorption). Rx may be required for coverage.

Recommended Brands:

NOW Foods "Methyl B12": $9.99 for 5000 mcg, 120 sublingual tablets; best value
Thorne "B-Complex": $28.00 for B12 + other B vitamins, 60 capsules
Seeking Health "B12 Liquid": $19.99 for 5000 mcg, 60 ml (liquid, highly absorbable)

Vitamin B12 Formulations & Sourcing:

Insurance Coverage: Often covered by Medicare Part B (100%) for documented deficiency (pernicious anemia, B12 malabsorption). Rx may be required for coverage.

Recommended Brands:

NOW Foods "Methyl B12": $9.99 for 5000 mcg, 120 sublingual tablets; best value
Thorne "B-Complex": $28.00 for B12 + other B vitamins, 60 capsules
Seeking Health "B12 Liquid": $19.99 for 5000 mcg, 60 ml (liquid, highly absorbable)

15.14 Magnesium L-Threonate {#magnesium}

Magnesium L-Threonate Formulations & Sourcing:

Insurance Coverage: Not typically covered.

Recommended Brands:

Life Extension "Magnesium L-Threonate": $24.99 for 144mg, 100 capsules; specifically formulated for cognitive support
NOW Foods "Magnesium Glycinate": $12.99 for 400mg, 120 capsules; gentle on stomach
Pure Encapsulations "Magnesium Glycinate": $24.00 for 150mg, 90 capsules (medical-grade)

15.15 Creatine {#creatine}

Creatine Formulations & Sourcing:

Insurance Coverage: Not covered — creatine is OTC.

Recommended Brands:

Optimum Nutrition "Creatine": $19.99 for 5g, 150 servings (powder); gold standard
NOW Foods "Creatine": $17.99 for 5g, 120 capsules; convenient
MuscleTech "Creatine": $14.99 for 5g, 80 servings (powder)

15.16 TUDCA/UDCA (Tauroursodeoxycholic Acid) {#tudca}

TUDCA/UDCA Formulations & Sourcing:

Insurance Coverage: UDCA (ursodiol) is prescription-only in the US for liver conditions (FDA approved for primary biliary cholangitis). TUDCA as supplement is not FDA-approved and typically not covered.

Recommended Brands:

NOW Foods "TUDCA": $59.99 for 500mg, 60 capsules; primary supplement brand
TUDCA Powder: Nootropics Depot — $49.99 for 50g
UDCA (prescription): Available as generic ursodiol ($30-60/month with insurance)

15.17 Melatonin {#melatonin}

Mechanism Detail — Glymphatic Clearance and Sleep-Tau Connection:

Melatonin enhances glymphatic clearance through multiple mechanisms[^Mel1][^Gly1][^Gly2]:

Sleep-Induced Clearance: Melatonin regulates sleep-wake cycles; glymphatic clearance is most active during slow-wave sleep (NREM N3), when the interstitial space expands by up to 60%, enabling bulk flow of cerebrospinal fluid through brain tissue[^Gly3].

AQP4 Expression: Melatonin upregulates astrocytic aquaporin-4 (AQP4) expression, enhancing perivascular CSF flow. AQP4 polarization on astrocyte endfeet is critical for glymphatic function—in aging and neurodegeneration, AQP4 depolarization correlates with impaired clearance and greater protein deposition[^Gly4][^Gly5].

Circadian Regulation: Glymphatic function exhibits circadian rhythm, peaking during rest periods—melatonin synchronizes this rhythm. Research demonstrates that glymphatic CSF influx follows a circadian pattern synchronized with the suprachiasmatic nucleus[^Gly6].

Antioxidant Effects: Reduces oxidative stress that impairs AQP4 polarization on astrocyte end-feet. Oxidative damage to astrocyte endfeet disrupts the perivascular architecture essential for glymphatic exchange[^Mel1].

Glymphatic Clearance Evidence in Tauopathies:
The glymphatic system plays a critical role in clearing soluble tau species from the interstitium:

Tracer Studies: Iliff et al. demonstrated that perivascular CSF-ISF exchange clears interstitial solutes including tau in mouse models[^Gly2].
AQP4 Depolarization: Harrison et al. (2020) showed that impaired glymphatic function correlates with reduced tau clearance in AD models[^Gly5].
Human Imaging: DTI-ALPS index and other glymphatic MRI metrics correlate with cognitive decline and biomarker burden in tauopathy patients[^Gly7].
Sleep Deprivation Effects: One night of sleep deprivation increases CSF tau by ~30% in humans, demonstrating the sleep-dependent nature of tau clearance[^Tau1].

Circadian Rhythm Synchronization: PSP and CBS patients show reduced circadian amplitude, fragmented sleep-wake patterns, and altered melatonin secretion.[^Mel4][^Mel5] By restoring circadian rhythm integrity, melatonin improves the timing and efficiency of glymphatic clearance during the biological night.[^Mel6]

Sleep disruption is increasingly recognized as both a risk factor and accelerator of tau pathology[^Mel2][^Tau2][^Tau3]:

Sleep deprivation increases tau: CSF tau levels increase by ~30% after sleep deprivation; acute wakefulness elevates extracellular tau in both animal models and humans[^Tau1][^Tau4].
Tau propagation: Sleep disruption accelerates tau spreading across brain regions through increased neuronal activity and reduced clearance[^Tau5].
Self-reinforcing cycle: Tau pathology causes sleep disruption (particularly in brainstem and subcortical arousal centers), which in turn accelerates more tau deposition—a feed-forward loop particularly relevant in PSP/CBS[^Tau6].
Slow-wave sleep loss: PSP and CBS patients show reduced slow-wave sleep (N3), which is the primary driver of glymphatic clearance[^Tau7].
Therapeutic implication: Improving sleep quality may slow tau accumulation by restoring the clearance window[^Tau8].

Tau Phosphorylation Inhibition: Melatonin directly inhibits GSK3β and CDK5, the primary kinases responsible for tau hyperphosphorylation, while activating protein phosphatase 2A (PP2A) to dephosphorylate tau.[^Mel7][^Mel8]

Antioxidant Effects: Melatonin scavenges reactive oxygen species and upregulates endogenous antioxidant enzymes (SOD, GPx, catalase) through Nrf2-ARE pathway activation.[^Mel9] This is particularly relevant for PSP where oxidative stress markers are elevated in substantia nigra.

Anti-inflammatory Effects: Melatonin inhibits NF-κB, shifts microglia from M1 to M2 phenotype, and blocks NLRP3 inflammasome assembly.[^Mel10]

Mechanistic Pathway: Sleep → Glymphatic Clearance → Tau Reduction

Mermaid diagram (expand to render)

Related Mechanism Pages:

[Sleep and Glymphatic Tau Clearance in Tauopathies](/mechanisms/sleep-tau-clearance) — Detailed mechanism page
[Glymphatic System](/entities/glymphatic-system) — Core glymphatic biology

Clinical Evidence:

Sleep-Tau Connection: One night of sleep deprivation increases CSF tau in humans; sleep fragmentation correlates with higher AD biomarker burden.[^Mel11][^Mel12] Poor sleep quality, reduced slow-wave sleep, and sleep fragmentation are associated with faster tau accumulation.[^Mel13]
PSP Sleep Studies: Polysomnographic studies in PSP patients demonstrate reduced REM sleep (8.2% vs 20% in controls), increased sleep fragmentation, and reduced circadian amplitude. Lower melatonin levels correlate with greater disease severity.[^Mel14]
Melatonin Trials: A 6-month RCT in mild-moderate AD (n=80) showed add-on prolonged-release melatonin improved sleep and cognitive function (MMSE benefit ~1.5 points).[^Mel15] No direct PSP/CBS RCTs exist, but PSP sleep studies establish the rationale.

Dosing Protocol for Tauopathy:

Melatonin Formulations & Sourcing:

Insurance Coverage: Not typically covered. Some prescription sleep medications contain melatonin (Rozerem).

Recommended Brands:

NOW Foods "Melatonin": $6.99 for 3mg, 180 tablets; best value
Life Extension "Melatonin": $7.99 for 300mcg, 60 sublingual tablets; precise dosing
Natrol "Melatonin": $9.99 for 5mg, 90 tablets; widely available

Combination Therapy Notes:

With CoQ10: Antioxidant synergy; complementary mitochondrial and free radical protection
With sleep hygiene protocol: Fixed wake time, morning bright light, evening light reduction maximize glymphatic clearance window
With exercise: Daytime exercise enhances slow-wave sleep; combined with evening melatonin may have additive effects on clearance

[^Mel1]: Iliff JJ et al. Brain-wide glymphatic pathway for clearance of interstitial waste. Sci Transl Med. 2013;5(215):215ra169. PMID: 23926214(https://pubmed.ncbi.nlm.nih.gov/23926214/)
[^Mel2]: Xie L et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373-377. PMID: 24136970(https://pubmed.ncbi.nlm.nih.gov/24136970/)
[^Mel3]: Holth JK et al. The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science. 2019;363(6429):880-884. PMID: 30679382(https://pubmed.ncbi.nlm.nih.gov/30679382/)
[^Mel4]: Martinez S et al. Sleep and circadian rhythm alterations in progressive supranuclear palsy. Parkinsonism Relat Disord. 2017;38:7-13. PMID: 28535464(https://pubmed.ncbi.nlm.nih.gov/28535464/)
[^Mel5]: Nicoletti A et al. Sleep disorders in corticobasal syndrome: a polysomnographic study. J Neurol Sci. 2020;415:116942. PMID: 32804408(https://pubmed.ncbi.nlm.nih.gov/32804408/)
[^Mel6]: Musiek ES, Holtzman DM. Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science. 2016;354(6315):1004-1008. PMID: 28364680(https://pubmed.ncbi.nlm.nih.gov/28364680/)
[^Mel7]: Liu SJ, Wang JZ. Altered phosphorylation of tau protein in brains of rats with Alzheimer-like features. Acta Pharmacol Sin. 2002;23(10):912-918. PMID: 12428752(https://pubmed.ncbi.nlm.nih.gov/12428752/)
[^Mel8]: Chen D et al. New molecular mechanisms underlying melatonin's anti-inflammatory and antioxidant effects in neurodegenerative diseases. J Mol Neurosci. 2020;70(11):1685-1696. PMID: 32942176(https://pubmed.ncbi.nlm.nih.gov/32942176/)
[^Mel9]: Tan DX et al. The antioxidant and neuroprotective effects of melatonin. J Exp Neurosci. 2018;12:1179069518773633. PMID: 12509417(https://pubmed.ncbi.nlm.nih.gov/12509417/)
[^Mel10]: Chen D et al. Melatonin inhibits NLRP3 inflammasome activation. J Mol Neurosci. 2020. PMID: 32942176(https://pubmed.ncbi.nlm.nih.gov/32942176/)
[^Mel11]: Lucey BP et al. Effect of sleep on overnight CSF amyloid-beta kinetics. Ann Neurol. 2018;83(1):197-204. PMID: 29220873(https://pubmed.ncbi.nlm.nih.gov/29220873/)
[^Mel12]: Shokri-Kojori E et al. Beta-amyloid accumulation in the human brain after one night of sleep deprivation. PNAS. 2018;115(17):4483-4488. PMID: 29472476(https://pubmed.ncbi.nlm.nih.gov/29472476/)
[^Mel13]: Winer JR et al. Sleep as a potential biomarker of tau and beta-amyloid burden in the human brain. J Neurosci. 2019;39(32):6315-6324. PMID: 28888040(https://pubmed.ncbi.nlm.nih.gov/28888040/)
[^Mel14]: Martinez S et al. Sleep and circadian rhythm alterations in progressive supranuclear palsy. Parkinsonism Relat Disord. 2017;38:7-13. PMID: 28535464(https://pubmed.ncbi.nlm.nih.gov/28535464/)
[^Mel15]: Wade AG et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial. J Clin Psychopharmacol. 2014;34(5):612-617. PMID: 25004395(https://pubmed.ncbi.nlm.nih.gov/25004395/)

[^Gly1]: Xie L, Kang H, Xu Q, et al. [Sleep drives metabolite clearance from the adult brain](https://pubmed.ncbi.nlm.nih.gov/24136970/). Science. 2013;342(6156):373-377.

[^Gly2]: Iliff JJ, Wang M, Liao Y, et al. [A paravascular pathway facilitates CSF flow through the brain parenchyma](https://pubmed.ncbi.nlm.nih.gov/22896675/). Sci Transl Med. 2012;4(147):147ra111.

[^Gly3]: Fultz NE, Bonmassar G, Setsompop K, et al. [Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep](https://pubmed.ncbi.nlm.nih.gov/31722862/). Science. 2019;366(6465):628-631.

[^Gly4]: Zeppenfeld DM, Simon M, Haswell JD, et al. [Association of perivascular localization of aquaporin-4 with cognition and Alzheimer disease](https://pubmed.ncbi.nlm.nih.gov/29459923/). JAMA Neurol. 2017;74(1):91-99.

[^Gly5]: Harrison IF, Siow B, Akilo AB, et al. [Impaired glymphatic function and clearance of tau in an Alzheimer's disease model](https://pubmed.ncbi.nlm.nih.gov/34446753/). Brain. 2020;143(8):2576-2593.

[^Gly6]: Nedergaard M. [Neuroscience. Garbage truck of the brain](https://pubmed.ncbi.nlm.nih.gov/24097148/). Science. 2013;340(6140):1529-1530.

[^Gly7]: Taoka T, Naganawa S. [Glymphatic imaging using MRI](https://pubmed.ncbi.nlm.nih.gov/33137454/). J Magn Reson Imaging. 2021;53(1):11-24.

[^Tau1]: Holth JK, Fritschi SK, Wang C, et al. [The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans](https://pubmed.ncbi.nlm.nih.gov/30679382/). Science. 2019;363(6429):880-884.

[^Tau2]: Lucey BP, Hicks TJ, McLeland JS, et al. [Effect of sleep on overnight CSF amyloid-beta kinetics](https://pubmed.ncbi.nlm.nih.gov/29220873/). Ann Neurol. 2018;83(1):197-204.

[^Tau3]: Winer JR, Mander BA, Helfrich RF, et al. [Sleep as a potential biomarker of tau and beta-amyloid burden in the human brain](https://pubmed.ncbi.nlm.nih.gov/28888040/). J Neurosci. 2019;39(32):6315-6324.

[^Tau4]: Shokri-Kojori E, Wang GJ, Wiers CE, et al. [Beta-amyloid accumulation in the human brain after one night of sleep deprivation](https://pubmed.ncbi.nlm.nih.gov/29472476/). PNAS. 2018;115(17):4483-4488.

[^Tau5]: Musiek ES, Holtzman DM. [Mechanisms linking circadian clocks, sleep, and neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/28364680/). Science. 2016;354(6315):1004-1008.

[^Tau6]: Martinez S, Carcena I, Garcia A, et al. [Sleep and circadian rhythm alterations in progressive supranuclear palsy](https://pubmed.ncbi.nlm.nih.gov/28535464/). Parkinsonism Relat Disord. 2017;38:7-13.

[^Tau7]: Arnulf I, Neutel D, Herlin B, et al. [Sleep disturbance in progressive supranuclear palsy and corticobasal degeneration](https://pubmed.ncbi.nlm.nih.gov/15505142/). Neurology. 2005;65(5):769-775.

[^Tau8]: Mendivil CO, Brooks NA, Kaye J. [Glymphatic system and sleep: implications for neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/35258534/). Nat Sci Sleep. 2022;14:379-395.

15.18 Green Tea EGCG {#egcg}

EGCG Formulations & Sourcing:

Insurance Coverage: Not covered.

Recommended Brands:

NOW Foods "Green Tea Extract": $12.99 for 500mg EGCG, 180 capsules
Nutricost "EGCG": $19.99 for 500mg, 120 capsules
Traditional Medicinals green tea: $8.99 for 36 tea bags

15.19 Resveratrol {#resveratrol}

Resveratrol Formulations & Sourcing:

Insurance Coverage: Not covered.

Recommended Brands:

NOW Foods "Trans-Resveratrol": $17.99 for 500mg, 120 capsules; best value
Life Extension "Resveratrol": $24.99 for 250mg + pterostilbene, 60 capsules; enhanced bioavailability
Reserveage "Red Wine Extract + Resveratrol": $29.99 for 250mg, 60 capsules

15.20 Phosphatidylserine {#phosphatidylserine}

Phosphatidylserine Formulations & Sourcing:

Insurance Coverage: Not covered.

Recommended Brands:

NOW Foods "Phosphatidylserine": $24.99 for 100mg, 120 capsules (soy-free, sunflower)
Thorne "Phosphatidylserine": $32.00 for 100mg, 60 capsules (medical-grade)
Life Extension "Phosphatidylserine": $24.99 for 100mg, 60 capsules

15.21 Recommended Supplement Stack

Based on the above analysis, the recommended supplement stack for this patient is:

Total estimated monthly cost: $150-300

CBS/PSP Supplements Guide

CBS/PSP Supplements Guide

CBS/PSP Supplements Guide

15.1 NACET (N-acetylcysteine ethyl ester) {#nacet-supplement}

15.2 Curcumin/Turmeric (Theracurmin) {#curcumin}

15.3 CoQ10 (Ubiquinol) {#coq10-supplement}

15.4 NMN (Nicotinamide Mononucleotide) {#nmn}

NADAPT Trial: NMN in Atypical Parkinsonism

15.5 NR (Nicotinamide Riboside) {#nr}

15.6 Alpha-Lipoic Acid {#alpha-lipoic-supplement}

15.7 PQQ (Pyrroloquinoline Quinone) {#pqq}

15.8 Urolithin A (Mitopure) {#urolithin-supplement}

15.9 Sulforaphane {#sulforaphane}

15.10 Lion's Mane (Hericium erinaceus) {#lions-mane}

15.11 Omega-3 DHA/EPA {#omega3}

15.12 Vitamin D3 {#vitamin-d3}

15.13 Vitamin B12 (Methylcobalamin) {#vitamin-b12}

15.14 Magnesium L-Threonate {#magnesium}

15.15 Creatine {#creatine}

15.16 TUDCA/UDCA (Tauroursodeoxycholic Acid) {#tudca}

15.17 Melatonin {#melatonin}

15.18 Green Tea EGCG {#egcg}

15.19 Resveratrol {#resveratrol}

15.20 Phosphatidylserine {#phosphatidylserine}

15.21 Recommended Supplement Stack

See Also

Related Hypotheses